Palvella Therapeutics (PVLA) Other Non-Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Other Non-Current Liabilities for 12 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 25.26% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 25.26% YoY), while the FY2025 annual figure was $2.0 million, up 23.92% from the prior year.
• Other Non-Current Liabilities grew to $2.2 million in Q1 2026 per PVLA's latest filing, from $2.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $2.2 million in Q1 2026 and bottomed at $1.0 million in Q4 2023.
• Historically, Other Non-Current Liabilities has averaged $1.8 million across 4 years, with a median of $1.8 million in 2025.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 62.43% — and 2025, when it gained 23.92%.
• Palvella Therapeutics' Other Non-Current Liabilities stood at $1.0 million in 2023, then surged by 62.43% to $1.6 million in 2024, then rose by 23.92% to $2.0 million in 2025, then rose by 5.68% to $2.2 million in 2026.
• Business Quant data shows PVLA's Other Non-Current Liabilities at $2.2 million in Q1 2026, $2.0 million in Q4 2025, and $1.9 million in Q3 2025.